Kidney Injury

Kidney injury refers to any damage or impairment to the kidneys, which are vital organs responsible for filtering waste products from the blood, maintaining fluid and electrolyte balance, and producing hormones. One significant form of kidney injury is acute kidney injury (AKI), characterized by a sudden and often severe decline in kidney function.

Background

Acute kidney injury is a common and serious complication, particularly among critically ill patients and those undergoing major procedures such as cardiac surgery.^[1]It is a major contributor to morbidity and mortality during hospitalization.^[1] Despite the severity of the condition, patients facing similar renal insults often experience remarkably different outcomes, suggesting that underlying genetic factors play a crucial role in an individual’s susceptibility to AKI.^[1] The definition of AKI often involves measuring increases in serum creatinine levels relative to a baseline, with various thresholds used to classify the severity of injury.^[1]

Biological Basis

The biological basis of kidney injury involves a complex interplay of physiological stressors and individual genetic predispositions. Genome-wide association studies (GWAS) have been instrumental in identifying common genetic markers, such as single-nucleotide polymorphisms (SNPs), that are linked to the risk of developing AKI.^[1] For instance, research has identified specific SNPs associated with AKI at two independent genetic loci. On chromosome 4, SNPs like rs62341639 and rs62341657 have been found near APOL1-regulator IRF2. On chromosome 22, SNPs such as rs9617814 and rs10854554 are located near the AKI-related gene TBX1.^[1] Other studies have also identified susceptibility loci, such as rs13317787 and rs10262995 (in BBS9), associated with AKI following coronary bypass graft surgery.^[2] Some identified SNPs may act as risk alleles, increasing susceptibility, while others may be protective, reducing the likelihood of developing AKI.^[1]

Clinical Relevance

The clinical impact of kidney injury, particularly AKI, is profound. Despite considerable efforts to develop treatments, therapeutic advancements aimed at preventing or mitigating AKI and accelerating recovery have largely been unsuccessful.^[1] Identifying genetic loci associated with an increased risk of AKI is critical, as it can unveil novel biological pathways that may be targeted for future therapeutic development.^[1] Genetic markers can also provide valuable prognostic information, potentially enhancing the prediction of postoperative AKI beyond traditional clinical risk factors.^[2] Understanding these genetic influences is expected to guide the development of more personalized and effective therapeutic strategies and patient management approaches.^[1]

Social Importance

The social importance of understanding and addressing kidney injury stems from its significant contribution to patient morbidity and mortality, particularly in vulnerable populations such as the critically ill and surgical patients.^[1]The high incidence of AKI in these settings places a substantial burden on healthcare systems and leads to adverse long-term outcomes for individuals. By enhancing the understanding of AKI pathophysiology through genetic research, there is potential to improve patient outcomes, reduce healthcare costs, and ultimately improve the quality of life for those at risk or affected by kidney injury.^[1]

Methodological and Statistical Constraints

Research into kidney injury is often constrained by study design and statistical power. While some studies leverage large meta-analyses to achieve substantial sample sizes, such as over 45,000 individuals in discovery and 18,000 in replication cohorts for kidney function decline, others face limitations in detecting genetic variants with moderate effects due to insufficient statistical power.^[3]For instance, some genome-wide association studies (GWAS) for acute kidney injury (AKI) may achieve 80% power to identify variants with specific odds ratios and minor allele frequencies, but this still leaves smaller effect sizes undetected.^[1] Challenges in replication are also noted, with some studies unable to successfully replicate all identified genetic loci, partly due to technical issues like primer design limitations or the lack of suitable external replication cohorts.^[1]Furthermore, heterogeneity across study cohorts can complicate interpretation. Differences between discovery and replication populations, such as varying patient selection criteria, baseline comorbidities like chronic kidney disease (CKD), cardiopulmonary bypass times, or types of cardiac surgical procedures, introduce variability.^[1] This cohort bias can lead to varying results, despite overlapping confidence intervals, and may necessitate extensive covariate adjustments. The design of studies also varies significantly, including differences in the length of follow-up for measuring kidney function decline, which can contribute to overall heterogeneity and potentially reduce the statistical power to identify consistent genome-wide significant associations.^[3]

Phenotypic Definition and Measurement Precision

Defining and measuring kidney injury, particularly acute kidney injury and kidney function decline, presents significant challenges that can impact research findings. There is no universally agreed-upon standard definition for renal function decline, and studies often rely on different criteria, such as specific percentage increases in serum creatinine over a baseline.^[3] While some studies implement stricter creatinine-based definitions to improve specificity for detecting intrinsic renal damage, they may lack other sensitive indicators like urine output data, which could provide a more comprehensive assessment of AKI.^[1] The precision of glomerular filtration rate (GFR) estimation equations is also a known limitation, especially at higher GFR values, and kidney function trajectories can be less accurately characterized with only two serum creatinine measurements compared to multiple time points, as changes may not be linear.^[3] Even when efforts are made to calibrate serum creatinine measurements to standardized reference values to mitigate inter-assay differences, other factors can still introduce imprecision in defining kidney function decline phenotypes.^[3]The unavailability of data on additional clinical variables, such as preoperative albuminuria, acute declines in renal function prior to surgery, or the perioperative use of renin-angiotensin system inhibitors, further limits the ability to refine AKI phenotypes and clinical risk scores.^[2] These measurement and definition inconsistencies can introduce noise into the data, potentially obscuring genuine genetic associations and contributing to reduced statistical power in genetic studies.

Generalizability and Unaccounted Confounding

A significant limitation of many genetic studies on kidney injury is the restricted ancestry of study populations, which impacts the generalizability of findings. Several genome-wide association studies (GWAS) specifically limit their analyses to individuals of European descent, either to avoid confounding from population admixture or due to the limited number of non-Caucasian patients in available datasets.^[3] Consequently, the identified genetic risk factors may not be directly applicable or transferable to other ethnic groups, highlighting a critical need for more diverse population cohorts in future research.

Furthermore, controlling for all potential confounders remains a challenge. While studies typically adjust for key clinical covariates such as diabetes, hypertension, CKD, and principal components related to ethnicity, the ability to condition replication populations on all relevant clinical covariates can be hindered by missing data or inherent differences in patient selection across cohorts.^[1] For example, self-reported race has been identified as an independent predictor of postoperative AKI, emphasizing the complex interplay of genetic and environmental factors.^[2]Unaccounted or inconsistently adjusted confounding factors can lead to inaccuracies in effect size estimations and potentially bias the observed genetic associations, making it difficult to isolate true genetic susceptibility.

Functional Validation and Remaining Knowledge Gaps

Despite the identification of promising genetic loci through GWAS, a common limitation is the absence of direct functional analyses to validate the observed genetic hits. While some studies provide indirect evidence for potential mechanistic roles, the precise biological pathways and cellular functions affected by these putative noncoding regulatory variants often remain speculative.^[2]Such functional follow-up would ideally involve detailed gene expression, eQTL, and allelic imbalance analyses, often requiring well-characterized animal models, which are not always readily available for specific kidney injury contexts like post-cardiac surgery AKI.^[2] Moreover, current GWAS methodologies are primarily designed to detect common genetic variants and may not adequately assay extremely rare, segmental variations (e.g., copy number variants, microsatellites), or somatic genetic variants.^[1]These types of variants may play significant roles in kidney injury susceptibility but require alternative sequencing techniques, such as whole-exome or whole-genome sequencing in relevant tissues, to be identified. The observation that identified SNPs and genetic loci often do not overlap with those reported in public databases or previous GWAS of renal diseases further underscores the complexity and remaining knowledge gaps in fully understanding the genetic architecture of kidney injury.^[1]

Variants

Genetic variations play a pivotal role in an individual’s susceptibility to kidney injury and the progression of kidney diseases. Single nucleotide polymorphisms (SNPs) can influence the function of genes, impacting cellular processes critical for kidney health. For example, studies have identified specific genetic loci, such as variants nearUMOD, that are significantly associated with changes in estimated glomerular filtration rate (eGFR), a key indicator of kidney function.^[3] Understanding these genetic influences helps elucidate the complex mechanisms underlying kidney disorders and potential targets for intervention.

One such variant, rs6874819 , is located in the region of the CDH12 gene, which encodes Cadherin 12. Cadherins are a family of calcium-dependent cell adhesion molecules crucial for maintaining cell-cell contacts and tissue integrity. In the kidney, cadherins are vital for the structural organization of nephrons and the proper function of cells like podocytes and tubular epithelial cells. A variant like rs6874819 could potentially alter CDH12 expression or protein function, thereby affecting cell adhesion and signaling pathways, which are critical for kidney development and its response to injury. Disruptions in cadherin-mediated adhesion can contribute to various kidney pathologies, similar to how genetic knockdown of CDH23 in zebrafish has been shown to result in altered renal function after nephrotoxic insults.^[3] Another variant, rs9580025 , is associated with LINC01046, a long intergenic non-coding RNA (lncRNA). LncRNAs are non-protein-coding RNA molecules that play diverse regulatory roles in gene expression, chromatin remodeling, and cellular processes. They are increasingly recognized as important modulators of kidney development, physiology, and disease pathogenesis. A variant withinLINC01046 could affect its stability, localization, or interaction with other molecules, thereby altering its regulatory capacity and potentially impacting kidney cell function or its ability to cope with stress. This is consistent with the emerging understanding that non-coding RNAs, such as LMCD1-AS1, can have critical roles in processes like recovery from acute kidney injury (AKI).^[4] The variant rs2957086 is found in a region encompassing DLGAP2 and DLGAP2-AS1. DLGAP2 encodes a scaffolding protein important for organizing protein complexes at cell junctions and synapses, crucial for cell polarity and signaling. While extensively studied in the nervous system, such scaffolding proteins are also essential for the structural and functional integrity of kidney cells, helping to maintain their specialized architecture and signaling pathways. DLGAP2-AS1 is an antisense RNA that can regulate the expression of DLGAP2. Therefore, rs2957086 could influence the expression levels or the function of either DLGAP2 or its antisense regulator, potentially disrupting cellular architecture or signaling in kidney cells. This type of genetic influence can be significant, as evidenced by the role of genes like CASP9 in cell apoptosis and inflammation within the kidney, which are critical responses to stress and injury.^[5]

Key Variants

RS ID	Gene	Related Traits
rs6874819	CDH12	kidney injury
rs9580025	LINC01046	kidney injury
rs2957086	DLGAP2, DLGAP2-AS1	kidney injury

Defining Kidney Injury: Conceptual Frameworks and Key Terminology

Kidney injury encompasses a broad spectrum of conditions characterized by structural or functional abnormalities of the kidneys, leading to a decline in their ability to effectively filter waste products from the blood.^[6]The primary conceptual framework distinguishes between Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD), representing conditions with distinct onset, progression, and clinical implications. Key terms foundational to understanding kidney injury include glomerular filtration rate (GFR), a crucial measure of kidney function, and its estimated variants (eGFR), as well as biomarkers like serum creatinine and cystatin C, which serve as primary indicators for diagnosis and monitoring.^[5]Chronic Kidney Disease (CKD) is precisely defined by the presence of kidney damage or decreased kidney function that persists for three or more months, irrespective of the underlying cause.^[7]A widely adopted operational definition for CKD, per the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines, is an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m².^[8]Conversely, Acute Kidney Injury (AKI) refers to a sudden and often reversible decline in kidney function, typically occurring over hours or days, characterized by rapid increases in serum creatinine and/or decreases in urine output.^[9]The distinction between these two major forms of kidney injury is critical for appropriate clinical management, research stratification, and prognostic assessment.

Classification and Severity Grading of Kidney Disease

The classification of kidney injury relies on standardized systems that categorize disease extent and prognosis, moving beyond simple presence or absence to incorporate severity gradations and subtypes. For Chronic Kidney Disease (CKD), the K/DOQI guidelines provide a comprehensive classification and stratification system primarily based on eGFR levels, with stages ranging from mild (Stage 1, characterized by normal GFR but other signs of kidney damage) to end-stage kidney disease (Stage 5, typically requiring dialysis or transplantation).^[10] A more severe CKD phenotype, sometimes termed CKD45, is defined by an eGFRcrea below 45 ml/min/1.73 m², indicating a more advanced stage of functional impairment and higher risk.^[5]Acute Kidney Injury (AKI) severity is graded using internationally recognized nosological systems such as RIFLE (Risk, Injury, Failure, Loss, End-stage kidney disease), AKIN (Acute Kidney Injury Network), and KDIGO (Kidney Disease: Improving Global Outcomes).^[2] These systems employ categorical criteria based on specific changes in serum creatinine and/or urine output to assign stages of increasing severity, providing a standardized approach for diagnosis and prognostication.^[9] Furthermore, the duration of AKI has been identified as an additional prognostic parameter, with prolonged episodes impacting long-term survival, highlighting the importance of considering temporal aspects beyond initial severity class.^[11] These classification systems facilitate consistent communication among clinicians and researchers and enable more precise patient management.

Diagnostic and Measurement Approaches

Accurate diagnosis and measurement of kidney injury are fundamental for both clinical practice and research, relying on a combination of clinical criteria, biomarkers, and established equations. The most common diagnostic criterion for assessing kidney function is the glomerular filtration rate (GFR), which is typically estimated (eGFR) using serum creatinine levels.^[7]Standardized equations, such as the Modification of Diet in Renal Disease (MDRD) Study equation and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, are widely employed to calculate eGFR from serum creatinine, often with creatinine measurements calibrated to national standards to ensure consistency across laboratories.^[7] Beyond creatinine, other biomarkers like serum cystatin C also serve as a basis for estimating GFR (eGFRcys), sometimes alone or in combination with creatinine, offering alternative or complementary assessments of kidney function.^[12]Specific thresholds and cut-off values are critical for defining kidney disease states: for instance, an eGFR below 60 ml/min/1.73 m² is a key diagnostic threshold for CKD, while a decline of 3 ml/min/1.73 m² per year or more signifies rapid kidney function decline.^[8] For AKI, diagnostic criteria often involve a relative increase in serum creatinine from a baseline level, such as a 25%, 50%, or 100% increase, with a 100% increase approximately equating to a 50% reduction in GFR.^[1]Albuminuria, measured as albumin excretion rate (AER) or albumin-to-creatinine ratio (ACR), is another crucial diagnostic marker, particularly for conditions like diabetic kidney disease, reflecting kidney damage even with preserved GFR.^[13] Clinical risk scores, integrating multiple preoperative and procedural variables, are also utilized to predict AKI risk in specific patient populations.^[2]

Causes of Kidney Injury

Kidney injury is a complex condition influenced by a confluence of genetic predispositions, environmental factors, and the presence of other health conditions. While acute kidney injury (AKI) often manifests as a sudden decline in renal function, underlying vulnerabilities can significantly increase an individual’s risk and shape the trajectory of the disease. Research highlights the importance of understanding these diverse causal pathways to improve prevention and treatment strategies.

Genetic Susceptibility and Polygenic Risk

Genetic factors play a substantial role in determining an individual’s susceptibility to kidney injury, even in response to similar physiological insults. Genome-wide association studies (GWAS) have identified several single-nucleotide polymorphisms (SNPs) and loci associated with an increased risk of acute kidney injury. For instance, specific genetic variants, such asrs62341639 and rs62341657 located on chromosome 4 near the APOL1-regulator IRF2 gene, have been linked to AKI development.^[1] Similarly, polymorphisms rs9617814 and rs10854554 on chromosome 22 near the TBX1 gene have also shown significant associations with AKI.^[1]Beyond these specific SNPs, the genetic landscape of kidney injury is often polygenic, involving multiple genes and their interactions. Studies on acute kidney injury after coronary bypass graft (CABG) surgery have identified susceptibility loci, includingrs13317787 at the chr3p21.6 locus and rs10262995 in BBS9, which influence the risk of postoperative AKI.^[2] Other genetic polymorphisms, such as the eNOS 786C/Tvariant and apolipoprotein E polymorphisms, have also been associated with renal dysfunction or postoperative creatinine levels in cardiac surgical patients.^[14] These findings underscore that inherited variants, often acting in concert, contribute to the varied outcomes observed among patients facing similar renal stressors.^[1]

Environmental Triggers and Acute Insults

Environmental factors and acute physiological insults are critical proximate causes of kidney injury, particularly acute forms. Major medical procedures, such as coronary artery bypass graft surgery, represent significant environmental triggers that can precipitate AKI.^[2] During such surgeries, factors like renal ischemia associated with cardiopulmonary bypass are direct insults to kidney function.^[1]While the researchs does not extensively detail lifestyle, diet, socioeconomic, or geographic factors for kidney injury, the context of acute injury emphasizes the role of direct exposures and medical interventions as primary environmental causes.

Comorbidities, Age, and Gene-Environment Interactions

The risk of kidney injury is significantly amplified by the presence of underlying health conditions, age, and complex interactions between an individual’s genetic makeup and their environment. Comorbidities such as diabetes mellitus, hypertension, and chronic kidney disease are well-established risk factors that are often adjusted for in genetic studies due to their profound impact on kidney health.^[1]Obesity has also been linked to kidney disease in both type 1 and type 2 diabetes, highlighting the systemic influence of metabolic health on renal function.^[15]Furthermore, the aging process inherently contributes to changes in renal function, with age-specific reference values for estimated glomerular filtration rate reflecting this decline.^[16]Crucially, the susceptibility to kidney injury often arises from gene-environment interactions, where genetic predispositions modulate an individual’s response to environmental triggers. For example, a “clinico-genomic model” that integrates genetic information with traditional clinical risk factors demonstrates improved prognostic value for postoperative AKI, indicating that genetic variants interact with surgical stress to determine outcomes.^[2] These interactions illustrate how inherited vulnerabilities can render individuals more susceptible to injury when exposed to specific stressors or living with certain comorbidities.

Biological Background

The kidneys are critical organs responsible for maintaining fluid and electrolyte balance, filtering waste products from the blood, and regulating blood pressure and red blood cell production. Acute kidney injury (AKI) signifies a sudden and often severe decline in these vital functions. Understanding the complex biological processes underlying kidney injury involves examining its pathophysiology, the molecular and cellular responses, genetic predispositions, and systemic interactions.

The Kidney’s Role and Pathophysiology of Injury

The kidneys play a vital role in maintaining the body’s homeostasis, and acute kidney injury represents a sudden decline in this essential function. AKI significantly contributes to morbidity and mortality during hospitalization, particularly in critically ill patients, with even small acute increases in serum creatinine associated with decreased long-term survival.^[17] A critical pathophysiological process leading to AKI involves renal ischemia, often observed in contexts like coronary bypass graft (CABG) surgery, where cardiopulmonary bypass (CPB) can induce renal ischemia.^[1]The duration of CPB is an independent predictor of morbidity and mortality following cardiac surgery, highlighting the systemic impact of these procedures on kidney health.^[18] Beyond ischemia, inflammatory conditions like endotoxemia and sepsis are major drivers of AKI. Endotoxin-induced renal failure is characterized by altered renal microcirculation.^[19] while TNF acting directly on TNF receptor-1 in the kidney is a key mechanism of acute renal failure in endotoxemia.^[20] During sepsis, Ly6Chigh monocytes protect against kidney damage through a CX3CR1-dependent adhesion mechanism, demonstrating the complex interplay of immune responses.^[21]AKI is not merely an acute event; it is also a significant risk factor for the development of chronic kidney disease (CKD), underscoring the long-term consequences of renal insults.^[11]

Cellular and Molecular Responses to Kidney Injury

At the cellular level, kidney injury triggers a cascade of molecular events involving various signaling pathways and cellular components. TheTGFβ–BMP signal pathway, for instance, is crucial during kidney development and can be implicated in AKI, with Tbx1 and HoxD10 interacting within this pathway.^[22] Increased Tbx1 expression, potentially via the TGFβ–Smad2/3signaling pathway, has been observed in acute kidney injury induced by gentamicin.^[23] Renal epithelial cells, including proximal tubules, respond to injury by producing IFNα stimulated by STAT1 and IRF1 during ischemic AKI, indicating an immune-inflammatory response.^[1] Furthermore, the VEGF-a signaling pathway plays a role in the glomerulus and induces branching morphogenesis and tubulogenesis in renal epithelial cells, suggesting its involvement in both normal kidney function and repair processes.^[24] Cellular integrity and function are also critical. Renal primary cilia, which are sensory organelles, have been observed to lengthen after acute tubular necrosis, suggesting a role in repair or response to injury.^[25] Polycystin-1is another crucial protein involved in renal injury repair and polycystic kidney disease, with its function linked to fluid flow dynamics.^[26] Metabolic disruptions, such as the generation of reactive oxygen species (ROS) within mitochondria, contribute to cellular toxicity in the kidney.^[27] Apoptosis, a form of programmed cell death, is regulated by proteins like Caspase-9, whose activity is modulated by phosphorylation.^[28]Specialized functions like proximal tubular phosphate reabsorption involve molecular mechanisms mediated by theSLC34family of sodium-phosphate cotransporters, includingNpt2a and Npt2c.^[29] while Claudin-14 regulates renal calcium transport in response to CaSR signaling via a microRNA pathway.^[30]

Genetic Predisposition and Regulatory Mechanisms

Genetic factors significantly influence an individual’s susceptibility to kidney injury, with genome-wide association studies (GWAS) identifying several loci linked to renal function and AKI.^[2]For instance, specific single-nucleotide polymorphisms (SNPs) have been identified near theAPOL1-regulator IRF2 and the AKI-related TBX1 genes, representing potential risk factors for AKI.^[1] Genetic polymorphisms in genes such as eNOS (specifically the 786C/T polymorphism) are associated with renal dysfunction in cardiac surgical patients.^[14]and variations in apolipoprotein E have been linked to postoperative peak serum creatinine concentrations and acute nephropathy after CABG.^[31] Other genes, including Thrombomodulin and Neuropeptide Y, also have polymorphisms associated with increased mortality or cardiovascular risk factors relevant to kidney health.^[32] Genetic mechanisms extend beyond individual SNPs to include broader gene functions and regulatory networks. Variants in UMOD(uromodulin) are associated with chronic kidney disease and kidney stones.^[16] The gene MYH9(myosin heavy chain 9) is a major-effect risk gene for focal segmental glomerulosclerosis and is associated with non-diabetic end-stage renal disease in African Americans.^[33]Susceptibility to kidney injury can also be influenced by the transfer of genomic segments, as demonstrated by increased susceptibility when a segment from SHR is transferred onto a Dahl S genetic background.^[34] Furthermore, studies on mouse models, such as Integrin alpha1/Akita double-knockout mice, reveal genetic contributions to conditions like diabetic nephropathy.^[35] Understanding these genetic variations and their impact on gene expression and regulatory elements, which can be explored through resources like RegulomeDB and HaploReg.^[36]is crucial for unraveling the complex etiology of kidney injury.

Systemic Consequences and Inter-organ Interactions

Kidney injury is rarely an isolated event, often exhibiting profound systemic consequences and interacting with other organ systems. The development of AKI significantly increases overall morbidity and mortality during hospitalization, and critically ill patients experiencing even small increases in serum creatinine face decreased long-term survival.^[17] The strong link between AKI and cardiac surgery, for example, highlights this systemic vulnerability, where procedures like coronary artery bypass grafting can precipitate renal injury.^[2]This interaction is further underscored by findings that decreased catecholamine degradation is associated with shock and kidney injury after cardiac surgery, indicating a role for adrenergic system dysregulation.^[37] The heritable influence of DBH on adrenergic and renal function further suggests a genetic component to this systemic connection.^[38]The systemic impact of kidney injury extends to the progression of chronic conditions. AKI is a significant risk factor for subsequent chronic kidney disease, highlighting a continuum of renal dysfunction.^[11]Conditions like atherosclerosis, influenced by gene polymorphisms such asNeuropeptide Y.^[39]can also contribute to the risk of renal injury, particularly in the context of cardiovascular procedures. The immune system’s role is also critical, with chemokines and their receptors being central to various renal diseases and their pathophysiological progression.^[40] Understanding the intricate tissue interactions and systemic consequences of AKI is essential for developing comprehensive therapeutic strategies that address not only the kidney but also the broader physiological environment.

Intracellular Signaling and Transcriptional Control

Kidney injury involves complex intracellular signaling cascades that regulate gene expression and cellular responses. TheTGFb–BMP signal pathway, for instance, is crucial during kidney development and can be dysregulated in injury.^[22] Specifically, increased Tbx1 expression can activate the TGFb–Smad2/3signaling pathway, contributing to acute kidney injury (AKI) induced by certain agents.^[23] Furthermore, the VEGF–a signaling pathway plays a vital role within the glomerulus, demonstrating crosstalk between components of the glomerular filtration barrier, and vascular endothelial growth factor (VEGF) is also known to induce branching morphogenesis and tubulogenesis in renal epithelial cells.^[24] During ischemic AKI, the APOL1-regulator IRF2 and IRF1 stimulate IFNa production by proximal tubules, highlighting the involvement of interferon regulatory factors in acute injury responses.^[1] Genetic variants near APOL1-regulator IRF2 and the TBX1 gene are identified as potential risk factors for AKI, suggesting their involvement in the underlying molecular mechanisms.^[1]

Cellular Stress, Metabolism, and Apoptotic Pathways

Cellular stress responses and metabolic dysregulation are central to the progression of kidney injury. Mitochondrial dysfunction and the generation of reactive oxygen species (ROS) contribute significantly to kidney toxicity, as seen in cases of cadmium exposure.^[27] The regulation of cell death pathways, such as apoptosis and autophagy, is also critical, with mechanisms like the phosphorylation of caspase-9 playing a key role in controlling these processes.^[28]In diabetic kidney disease (DKD), the RNA maturation factorSCAF8 (also known as RBM16) acts as a target for ATM kinase, a crucial component of the DNA damage response system responsible for DNA repair and cell cycle control.^[41]This highlights how pathways involved in maintaining genomic integrity and cellular turnover are intimately linked to kidney health and disease.

Structural and Mechanosensory Mechanisms

The structural integrity and mechanosensory functions of kidney cells are crucial for maintaining renal function and responding to injury. Renal primary cilia, which are essential mechanosensors, undergo lengthening after acute tubular necrosis, suggesting their involvement in the repair process.^[25] The function of polycystin-1, a protein associated with primary cilia, is also implicated in polycystic kidney disease and renal injury repair, highlighting common pathways influenced by fluid flow and mechanotransduction.^[26] Integrins, such as integrin alpha1, are vital for cell-matrix interactions, and their dysregulation can contribute to kidney pathology, as evidenced by diabetic nephropathy development in integrin alpha1/Akita double-knockout mice.^[35] Furthermore, MYH9is identified as a major-effect risk gene for focal segmental glomerulosclerosis and is associated with non-diabetic end-stage renal disease in certain populations, pointing to the importance of cytoskeletal proteins in maintaining glomerular structure and function.^[42]

Neurohormonal and Systemic Regulatory Networks

Kidney injury is often influenced by intricate neurohormonal and systemic regulatory networks, involving extensive pathway crosstalk and hierarchical regulation. The renin-angiotensin-aldosterone system (RAAS) plays a significant role, with inhibition of aldosterone proving effective in limiting renal fibrosis and slowing DKD progression.^[41] Genetic variants such as the eNOS 786C/T polymorphism have been associated with renal dysfunction in cardiac surgical patients, indicating the impact of endothelial nitric oxide synthase on kidney health.^[14]Additionally, decreased catecholamine degradation is linked to shock and kidney injury following cardiac surgery, demonstrating the systemic influence of adrenergic pathways on renal outcomes.^[37] Variants in UMODare associated with chronic kidney disease and kidney stones, underscoring the genetic predisposition to renal dysfunction influenced by protein processing and transport.^[16] The protein CNKSR3 is also relevant to DKD, with further studies needed to determine if it regulates pathogenesis indirectly via effects on ENaCactivity or directly through aldosterone-dependent fibrosis.^[41]

Prognostic Impact and Long-Term Outcomes

Acute kidney injury (AKI) significantly contributes to morbidity and adverse long-term outcomes following hospitalization. Research indicates that even minor acute increases in serum creatinine, which might not meet the full diagnostic criteria for AKI, are associated with decreased long-term survival in critically ill patient populations.^[43] The duration of AKI is a particularly crucial prognostic factor, with prolonged episodes predicting poorer long-term survival, especially noted in diabetic veterans and individuals undergoing cardiac surgery.^[11]The impact of AKI extends beyond the immediate acute phase, as it is a recognized and significant risk factor for the development and progression of chronic kidney disease (CKD).^[11]This highlights the necessity for meticulous follow-up and management strategies post-AKI to mitigate the risk of subsequent chronic kidney dysfunction. Furthermore, the percentage change in serum creatinine (%ΔCr), even when below established dichotomous AKI thresholds, reflects a spectrum of kidney injury and is independently associated with substantial reductions in post-operative event-free survival, underscoring its broad prognostic utility.^[2]

Diagnostic Utility and Clinical Risk Assessment

Accurate and timely diagnosis of kidney injury is paramount for effective patient management and intervention. Clinical applications encompass the use of consensus definitions such as KDIGO, AKIN, and RIFLE criteria for diagnosing and staging AKI, although continuous markers like %ΔCr are recognized for their enhanced power in identifying genetic risk variants compared to dichotomous outcomes.^[2]Beyond traditional creatinine-based definitions, emerging biomarkers, including urine neutrophil gelatinase-associated lipocalin (NGAL) and B-type natriuretic peptide (BNP), have demonstrated utility in predicting AKI and poor outcomes after adult cardiac surgery, as well as hospital length of stay and mortality.^[44]Risk assessment is a fundamental component of prevention and early intervention strategies. Multivariable clinical AKI risk scores, which integrate factors such as preoperative creatinine, patient weight, aortic cross-clamp time, perioperative transfusion, and hypertension, have been developed to predict renal dysfunction following procedures like coronary artery bypass graft (CABG) surgery.^[2]These comprehensive scores, alongside other predictors such as pulse pressure hypertension and cardiopulmonary bypass duration, aid in identifying individuals at elevated risk for nephrological morbidity, thereby guiding proactive measures to minimize kidney injury.^[45]

Genomic Insights for Personalized Risk Stratification

Genetic factors significantly influence an individual’s susceptibility to kidney injury, opening pathways for personalized medicine and refined risk stratification. Genome-wide association studies (GWAS) have successfully identified specific susceptibility loci that contribute to the risk of acute kidney injury after events such as coronary bypass graft surgery.^[1]For instance, specific single-nucleotide polymorphisms (SNPs) likers13317787 and rs10262995 have been identified as genetic markers, with genotype information at these loci shown to improve the predictive performance of existing clinical AKI risk scores.^[2] These genomic findings suggest the potential for developing advanced pre-operative risk stratification tools. By individually assessing risk alleles of rs13317787 and rs10262995 , it may be possible to identify cardiac surgery patients who face a considerably elevated AKI risk (demonstrating a 1.5–5 fold greater rise in serum creatinine) compared to non-carriers, even prior to surgical intervention.^[2] Integrating such genetic insights with traditional clinical risk factors could lead to more precise identification of high-risk individuals, enabling the implementation of tailored preventative measures or more intensive monitoring strategies to improve patient outcomes.

Associated Comorbidities and Clinical Context

Kidney injury frequently coexists with or is influenced by a range of comorbidities, underscoring its complex interplay within systemic health. Chronic kidney disease (CKD), defined as a baseline estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73m², represents a significant pre-existing condition that increases an individual’s vulnerability to acute kidney injury.^[1]Other common comorbidities, including diabetes mellitus and hypertension, are consistently adjusted for in studies of kidney injury, highlighting their well-established roles as risk factors and contributing pathologies.^[1]Beyond these prevalent conditions, specific clinical contexts, such as aortic atherosclerosis, particularly in the setting of cardiac surgery, have been associated with acute nephropathy, with genetic factors like apolipoprotein E polymorphisms potentially modulating this risk.^[46]Furthermore, specific biological pathways involving increased plasma catalytic iron in patients may mediate acute kidney injury and death following cardiac surgery, pointing to targeted mechanisms linking systemic issues to renal damage.^[47]The occurrence of renal dysfunction after myocardial revascularization further illustrates the close association between cardiovascular health and kidney function.^[48]

Frequently Asked Questions About Kidney Injury

These questions address the most important and specific aspects of kidney injury based on current genetic research.

---

1. Why do some people get kidney injury after surgery, but I might not?

Your genes play a significant role! Even if two people undergo the same surgery or face similar stressors, their individual genetic makeup can make one more susceptible to acute kidney injury (AKI) than the other. For instance, specific genetic markers near genes likeIRF2 on chromosome 4 or TBX1 on chromosome 22 have been linked to AKI risk. Some people naturally have protective genetic variations, while others have risk alleles.

2. Can my family history make me more prone to kidney problems?

Yes, absolutely. If kidney injury or susceptibility runs in your family, it suggests you might have inherited some of the genetic factors that increase your risk. Research has identified various genetic markers, such as specific single-nucleotide polymorphisms (SNPs), that contribute to an individual’s likelihood of developing conditions like acute kidney injury. These genetic predispositions are passed down through generations.

3. Could a gene test tell me if I’m at higher risk for kidney injury?

Potentially, yes. Identifying certain genetic markers, like SNPs, can provide valuable information about your individual susceptibility to kidney injury, especially after events like surgery. While not yet routine for everyone, understanding these genetic predispositions, such as variations nearBBS9 for post-surgery AKI, could help predict risk beyond traditional factors and guide personalized care in the future.

4. If I’m very sick, do my genes affect my kidney injury risk?

Yes, your genetic background significantly influences how your kidneys respond to severe physiological stress, like being critically ill. The biological basis of kidney injury involves a complex interaction between these stressors and your unique genetic predispositions. Some genetic variations might make your kidneys more vulnerable to damage when you’re critically ill.

5. Why do some people recover fast from kidney injury, but others struggle?

Individual genetic differences are a major reason for varied recovery outcomes. Even when facing similar kidney insults, people’s bodies react and recover differently due to their unique genetic profiles. Some genetic variations might support quicker recovery, while others could hinder it, making recovery from acute kidney injury more challenging for some individuals.

6. Does my individual genetic makeup impact how my kidneys handle stress?

Yes, it certainly does. Your unique genetic makeup determines how resilient your kidneys are to various physiological stressors, whether from illness, surgery, or other factors. For example, specific SNPs identified near genes like IRF2 and TBX1 are known to influence how your kidneys respond to and recover from injury.

7. Will doctors eventually use my DNA to tailor my kidney care?

That’s the goal for future medicine. Understanding your specific genetic influences, such as identifying risk alleles, is expected to guide the development of more personalized and effective therapeutic strategies. This could mean doctors using your genetic information to predict risk, choose the best treatments, or even prevent kidney injury.

8. Why don’t standard treatments work for everyone with kidney injury?

One key reason is the strong influence of individual genetic factors. Since underlying genetics play a crucial role in a person’s susceptibility and response to kidney injury, a “one-size-fits-all” approach often falls short. What works for one person might not be effective for another due to their unique genetic predispositions.

9. If I have specific gene variations, can doctors plan my kidney care better?

Yes, that’s a significant area of research and future potential. Knowing your specific genetic variations that increase your risk for kidney injury, like those nearAPOL1-regulator IRF2 or TBX1, can help doctors anticipate problems and develop more targeted, personalized strategies for your care. This could lead to more effective prevention or earlier intervention.

10. Are some people just born with kidneys more vulnerable to damage?

Yes, in a way, some individuals are born with a genetic predisposition that makes their kidneys inherently more vulnerable to damage. Genome-wide association studies (GWAS) have identified specific genetic markers, or SNPs, that are linked to an increased risk of developing conditions like acute kidney injury, meaning this susceptibility can be present from birth.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Zhao, B., et al. “A Genome-Wide Association Study to Identify Single-Nucleotide Polymorphisms for Acute Kidney Injury.”Am J Respir Crit Care Med, 2016.

[2] Stafford-Smith M, et al. Genome-wide association study of acute kidney injury after coronary bypass graft surgery identifies susceptibility loci.Kidney Int. 2015;88(4):823-832.

[3] Gorski, M et al. “Genome-wide association study of kidney function decline in individuals of European descent.” Kidney Int, vol. 87, no. 5, 2014, pp. 1017-27.

[4] Stafford-Smith, M et al. “Genome-wide association study of acute kidney injury after coronary bypass graft surgery identifies susceptibility loci.”Kidney Int, vol. 89, no. 4, 2016, pp. 917-26.

[5] Pattaro, C et al. “Genome-wide association and functional follow-up reveals new loci for kidney function.” PLoS Genet, vol. 8, no. 3, 2012, e1002584.

[6] Meguid El Nahas, A., and A. K. Bello. “Chronic kidney disease: The global challenge.”Lancet, vol. 365, no. 9456, 2005, pp. 331–340.

[7] Levey, A. S., J. P. Bosch, J. B. Lewis, et al. “A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group.”Annals of Internal Medicine, vol. 130, no. 6, 1999, pp. 461–470.

[8] Yasukochi, Y., Y. Kamatani, N. Okada, et al. “Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.”Molecular Genetics and Genomics, vol. 292, no. 6, 2017, pp. 1345-1353.

[9] Bellomo, R., C. Ronco, J. A. Kellum, et al. “Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.” Critical Care, vol. 8, 2004, pp. R204–R212.

[10] National Kidney Foundation. “K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification.”American Journal of Kidney Diseases, vol. 39, no. 2, Suppl 1, 2002, pp. S1–266.

[11] Coca SG, et al. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis.Kidney Int. 2012;81(5):442-448.

[12] Stevens, L. A., J. Coresh, C. H. Schmid, et al. “Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with CKD.” American Journal of Kidney Diseases, vol. 51, no. 3, 2008, pp. 395–406.

[13] van Zuydam, N. R., A. J. Ahlqvist, R. J. Boucher, et al. “A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes.”Diabetes, vol. 66, no. 10, 2017, pp. 2719-2729.

[14] Popov, A. F., et al. “The eNOS 786C/T polymorphism in cardiac surgical patients with cardiopulmonary bypass is associated with renal dysfunction.” Eur J Cardiothorac Surg, vol. 36, 2009, pp. 651–656.

[15] Hill, C. J., et al. “Obesity and kidney disease in type 1 and 2 diabetes: an analysis of the National Diabetes Audit.”QJM, vol. 106, no. 10, 2013, pp. 933–939.

[16] Gudbjartsson, D. F., et al. “Association of variants at UMODwith chronic kidney disease and kidney stones-role of age and comorbid diseases.”PLoS Genet, vol. 6, 2010, pp. e1001039.

[17] Waikar, S. S., Liu, K. D., & Chertow, G. M. “Diagnosis, epidemiology and outcomes of acute kidney injury.”Clin J Am Soc Nephrol, vol. 3, 2008.

[18] Salis S, et al. Cardiopulmonary bypass duration is an independent predictor of morbidity and mortality after cardiac surgery.J Cardiothorac Vasc Anesth. 2008;22(6):814-822.

[19] Heyman, S. N., et al. “Endotoxin-induced renal failure. I. A role for altered renal microcirculation.” Exp Nephrol, vol. 8, 2000, pp. 266–274.

[20] Cunningham, P. N., et al. “Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney.” J Immunol, vol. 168, 2002, pp. 5817–5823.

[21] Chousterman, B. G., et al. “Ly6Chigh monocytes protect against kidney damage during sepsis via a CX3CR1-dependent adhesion mechanism.” J Am Soc Nephrol, vol. 27, 2016, pp. 792–803.

[22] Fu, Y., et al. “Interaction between Tbx1 and HoxD10 and connection with TGFβ–BMP signal pathway during kidney development.” Gene, vol. 536, 2014, pp. 197–202.

[23] Jiang, H., et al. “Increased Tbx1 expression may play a role via TGFβ–Smad2/3signaling pathway in acute kidney injury induced by gentamicin.”Int J Clin Exp Pathol, vol. 7, 2014, pp. 1595–1605.

[24] Eremina, V., Baelde, H. J., & Quaggin, S. E. “Role of the VEGF-a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier.” Nephron Physiol, vol. 106, 2007, pp. 32–37.

[25] Verghese, E., et al. “Renal primary cilia lengthen after acute tubular necrosis.” J Am Soc Nephrol, vol. 20, 2009, pp. 2147–2153.

[26] Weimbs, T. “Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the function ofpolycystin-1.” Am J Physiol Renal Physiol, vol. 293, 2007, pp. F1423–F1432.

[27] Gobe, G., & Crane, D. “Mitochondria, reactive oxygen species and cadmium toxicity in the kidney.” Toxicol Lett, vol. 198, no. 1, 2010, pp. 49–55.

[28] Allan, L. A., & Clarke, P. R. “Apoptosis and autophagy: Regulation of caspase-9 by phosphorylation.” FEBS J, vol. 276, no. 21, 2009, pp. 6063–6073.

[29] Murer, H., et al. “Proximal tubular phosphate reabsorption: molecular mechanisms.”Physiol Rev, vol. 80, 2000, pp. 1373–1409.

[30] Gong, Y., et al. “Claudin-14 regulates renal Ca(++) transport in response to CaSR signalling via a novel microRNA pathway.” EMBO J.

[31] Chew, S. T., et al. “Preliminary report on the association of apolipoprotein E polymorphisms, with postoperative peak serum creatinine concentrations in cardiac surgical patients.”Anesthesiology, vol. 93, 2000, pp. 325–331.

[32] Lobato, R. L., et al. “Thrombomodulingene variants are associated with increased mortality after coronary artery bypass surgery in replicated analyses.”Circulation, vol. 124, 2011, pp. S143–S148.

[33] Kottgen, A., et al. “MYH9is associated with nondiabetic end-stage renal disease in African Americans.”Nat Genet, vol. 40, 2008, pp. 1185–1192.

[34] Regner, K. R., et al. “Increased susceptibility to kidney injury by transfer of genomic segment from SHR onto Dahl S genetic background.”Physiol Genomics, vol. 44, 2012, pp. 629–637.

[35] Yu, L., et al. “Integrin alpha1/Akita double-knockout mice on a Balb/c background develop advanced features of human diabetic nephropathy.” Kidney Int, vol. 81, 2012, pp. 1086–1097.

[36] Boyle, A. P., et al. “Annotation of functional variation in personal genomes using RegulomeDB.” Genome Res, vol. 22, 2012, pp. 1790–1797.

[37] Haase-Fielitz, A., et al. “Decreased catecholamine degradation associates with shock and kidney injury after cardiac surgery.”J Am Soc Nephrol, vol. 20, 2009, pp. 1393–1403.

[38] Pasha, D. N., et al. “Heritable influence of DBHon adrenergic and renal function: twin and disease studies.”PLoS One, vol. 8, 2013, pp. e82956.

[39] Shah, S. H., et al. “Neuropeptide Ygene polymorphisms confer risk of early-onset atherosclerosis.”PLoS Genet, vol. 5, 2009, pp. e1000318.

[40] Segerer, S., Nelson, P. J., & Schlondorff, D. “Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies.”J Am Soc Nephrol, vol. 11, 2000, pp. 152–176.

[41] Iyengar, S. K., et al. “Genome-Wide Association and Trans-ethnic Meta-Analysis for Advanced Diabetic Kidney Disease: Family Investigation of Nephropathy and Diabetes (FIND).”PLoS Genet, vol. 11, no. 8, 2015, e1005321.

[42] Kopp, J. B., et al. “MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.” Nat Genet, vol. 40, 2008, pp. 1175–1184.

[43] Linder A, et al. Small acute increases in serum creatinine are associated with decreased long-term survival in the critically ill. Am J Respir Crit Care Med. 2014;189(9):1075-1081.

[44] Siew ED, et al. Urine neutrophil gelatinase–associated lipocalin moderately predicts acute kidney injury in critically ill adults.J Am Soc Nephrol. 2009;20(8):1823-1832.

[45] Aronson S, et al. Risk index for perioperative renal dysfunction/failure: critical dependence on pulse pressure hypertension.Circulation. 2007;115(6):733-742.

[46] MacKensen GB, et al. Preliminary report on the interaction of apolipoprotein E polymorphism with aortic atherosclerosis and acute nephropathy after CABG.Ann Thorac Surg. 2004;78(2):520-526.

[47] Leaf DE, et al. Increased plasma catalytic iron in patients may mediate acute kidney injury and death following cardiac surgery.Kidney Int. 2015;87(5):1046-1054.

[48] The Multicenter Study of Perioperative Ischemia Research Group. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. Ann Intern Med. 1998;128(3):194-203.